
Bristol Myers debuts first Opdualag campaign, adds to its two-combo cancer drug marketing
Bristol Myers Squibb’s first campaign for Opdualag marks a second stake in the ground for the biopharma. The new work is its second immuno-oncology combo drug, direct-to-consumer (DTC) ad campaign, with both efforts now running on TV, social and digital media.
Opdualag, approved in March 2022, is a combination of Bristol Myers’ blockbuster PD-1 Opdivo (nivolumab) and relatlimab, approved to treat advanced melanoma cancer. The second campaign is an ongoing effort for Opdivo plus Yervoy, with new creative added in December.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.